SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 14D9 - Solicitation, recommendation statements:
SEC Accession No. 0001193125-24-203615
Filing Date
2024-08-20
Accepted
2024-08-20 15:40:55
Documents
5

Document Format Files

Seq Description Document Type Size
1 SC 14D9 d856692dsc14d9.htm SC 14D9 607492
2 EX-99.(E)(2) d856692dex99e2.htm EX-99.(E)(2) 41545
3 EX-99.(E)(3) d856692dex99e3.htm EX-99.(E)(3) 9156
4 EX-99.(E)(4) d856692dex99e4.htm EX-99.(E)(4) 10644
5 GRAPHIC g856692dsp_42.jpg GRAPHIC 4108
  Complete submission text file 0001193125-24-203615.txt   676599
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filed by) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 14D9
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Subject) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 14D9 | Act: 34 | File No.: 005-90214 | Film No.: 241224966
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)